Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 5

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 5
---
 biomarker laws. Myriad Genetics continues to engage this payor, providing additional data that supports the value of the GeneSight test. Importantly, the overall strength of Myriad Genetics' diversified laboratory model is nonetheless expected to generate growth in 2025 despite these headwinds.

The research and development investments that we have made in the past three years are starting to bear fruit with an emerging body of clinical evidence that we believe will support guideline expansion, clinical utility and adoption, and improved reimbursement over the next few years. We continue to invest in generating clinical evidence for our Molecular Residual Disease (MRD) test, Precise MRD, which offers exceptional levels of sensitivity. We announced the issuance of five U.S. patents covering our MRD test, as well as a cross-license with Personalis of patent estates covering tumor-informed approaches to detect molecular residual disease. In addition, we announced a series of research collaborations to study the use of our MRD assay involving researchers at The University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and the National Cancer Center Hospital East in Japan, and a study partnership with Aptitude Health. We currently have approximately 20 studies, including more than 4,000 patients and 30,000 data points, being run at these and other top cancer institutions in the world. These studies are evaluating Precise MRD across a range of cancer indications, with data expected to be published in 2025 and beyond.

Our robust product pipeline includes FirstGene TM multiple prenatal screen, expanded MyRisk with RiskScore, Precise MRD, and Prostate PATHOMIQ PRAD test, and Precise Liquid comprehensive genomic panel. We look forward to continuing to provide differentiated insights and clinical utility to healthcare providers and their patients.

Digital Technology Enabling Seamless Customer Experience

Enabling increasingly digital workflows is critical to providing a positive customer experience, and we continued to invest significantly in these capabilities in 2024 to deliver value to patients and providers in real-world clinical settings to enable better treatment decisions. We focused on making it easier to do business with us across the entire customer journey, from exploring our products to ordering tests, and receiving easy-to-understand results with actionable insights.

We continue to improve our online capabilities to streamline provider, patient, and payor engagement. We have unified and automated our order management system and customer portals for patients and providers to enable easier ordering and reporting of test results.

We completed electronic medical record (EMR) integrations from more than 1,500 locations